Market Place
Sourcing Support
Ligand Hosts 2024 Investor & Analyst Day & Introduces Guidance
10 Dec 2024 //
BUSINESSWIRE
Lig& Reports Q3 2024 Financial Results & Raises 2024 Guidance
07 Nov 2024 //
BUSINESSWIRE
Ligand to Host Investor Day on Dec 10, 2024 in Boston
01 Nov 2024 //
BUSINESSWIRE
Ligand Q3 2024 Financial Results on November 7
23 Oct 2024 //
BUSINESSWIRE
Ligand Partner Travere Gets Full FDA Approval For FILSPARI In IgA
06 Sep 2024 //
BUSINESSWIRE
Ligand to Present at H.C. Wainwright 26th Annual Global Investment Conference
20 Aug 2024 //
BUSINESSWIRE
Ligand Reports Second Quarter 2024 Financial Results
06 Aug 2024 //
BUSINESSWIRE
Ligand to Report Second Quarter 2024 Financial Results on August 6, 2024
23 Jul 2024 //
BUSINESSWIRE
Ligand to Acquire APEIRON Biologics AG for $100 Million
08 Jul 2024 //
BUSINESSWIRE
Ligand Collaborator Merck Receives FDA Approval For CAPVAXIVE™ For Adults
18 Jun 2024 //
BUSINESSWIRE
Ligand to Participate in Upcoming Investor Conferences
23 May 2024 //
BUSINESSWIRE
Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement
07 May 2024 //
BUSINESSWIRE
Ligand Reports First Quarter 2024 Financial Results
07 May 2024 //
BUSINESSWIRE
Ligand to Report First Quarter 2024 Financial Results on May 7, 2024
23 Apr 2024 //
BUSINESSWIRE
Ligand Announces New Topiramate Data Presented at the Conference
08 Apr 2024 //
BUSINESSWIRE
Ligand Pharma Announces Launch of Pelthos Thera to Commercialization of ZELSUVMI
03 Apr 2024 //
BUSINESSWIRE
Ligand to Present at Barclays 26th Annual Global Healthcare Conference
05 Mar 2024 //
BUSINESSWIRE
Ligand Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 Mar 2024 //
BUSINESSWIRE
Ligand Reports Fourth Quarter and Full Year 2023 Financial Results
27 Feb 2024 //
BUSINESSWIRE
Ligand Partner Eisai Receives Approval for Injection Formulation of Fycompa
22 Feb 2024 //
BUSINESSWIRE
Ligand Pharmaceuticals Expands Senior Leadership Team with Two Key Hires
16 Feb 2024 //
BUSINESSWIRE
Ligand to Report Fourth Quarter and Full Year 2023 Financial Results
13 Feb 2024 //
BUSINESSWIRE
Ligand Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 Feb 2024 //
BUSINESSWIRE
Ligand crosses FDA finish line with molluscum gel Zelsuvmi
07 Jan 2024 //
FIERCE PHARMA
Ligand Pharma`s at-home viral skin infection treatment gets US approval
06 Jan 2024 //
REUTERS
FDA Approves ZELSUVMI™ as a First-in-Class Medication for Molluscum Contagiosum
05 Jan 2024 //
BUSINESSWIRE
Ligand Holds Investor and Analyst Day
12 Dec 2023 //
BUSINESSWIRE
Palvella Therapeutics and Ligand Pharmaceuticals Expand Strategic Partnership
01 Dec 2023 //
GLOBENEWSWIRE
Ligand Reports Third Quarter 2023 Financial Results
08 Nov 2023 //
BUSINESSWIRE
Ligand Acquires Royalty on Sanofi’s TZIELD® for $20 Million
01 Nov 2023 //
BUSINESSWIRE
Ligand To Report Third Quarter 2023 Financial Results On November 8
25 Oct 2023 //
BUSINESSWIRE
Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement
18 Oct 2023 //
GLOBENEWSWIRE
Ligand Acquires Assets of Novan, Inc. for $12.2 Million
27 Sep 2023 //
BUSINESSWIRE
Ligand Appoints Martine Zimmermann to its Board of Directors
26 Sep 2023 //
BUSINESSWIRE
Ligand’s Partner Jazz Pharmaceuticals Receives ECA for Enrylaze
22 Sep 2023 //
BUSINESSWIRE
Ligand Spins Out and Merges Pelican Subsidiary with Primordial Genetics
18 Sep 2023 //
BUSINESSWIRE
Ligand Pharma Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
01 Sep 2023 //
BUSINESSWIRE
Ligand Reports Second Quarter 2023 Financial Results
08 Aug 2023 //
BUSINESSWIRE
Ligand To Report Second Quarter 2023 Financial Results On August 8
25 Jul 2023 //
BUSINESSWIRE
Ligand Offers $15 Million to Acquire Assets of Novan, Inc.
17 Jul 2023 //
BUSINESSWIRE
Ligand Reports First Quarter 2023 Financial Results
04 May 2023 //
BUSINESSWIRE
Ligand to Report First Quarter 2023 Financial Results on May 4, 2023
25 Apr 2023 //
BUSINESSWIRE
Ligand Reports Fourth Quarter and Full Year 2022 Financial Results
22 Feb 2023 //
BUSINESSWIRE
Ligand to Report Fourth Quarter Financial Results on February 22
06 Feb 2023 //
BUSINESSWIRE
Ligand’s Partner Novan Submits NDA to the U.S. FDA for Berdazimer Gel
06 Jan 2023 //
BUSINESSWIRE
Ligand Provides Highlights from its Investor and Analyst Day Event
13 Dec 2022 //
BUSINESSWIRE
Ligand Pharmaceuticals Names Todd Davis as CEO
05 Dec 2022 //
BUSINESSWIRE
Ligand to Hold Investor and Analyst Day on December 13
16 Nov 2022 //
BUSINESSWIRE
Ligand Reports Third Quarter 2022 Financial Results
07 Nov 2022 //
PRESS RELEASE
Ligand Distribution of OmniAb Complete and Business Combination Closed
01 Nov 2022 //
BUSINESSWIRE
Ligand Announces Completion of OmniAb Spin-Off
01 Nov 2022 //
BUSINESSWIRE
Ligand Announces that Janssen has Received Approval from U.S. FDA for TECVAYLI
26 Oct 2022 //
BUSINESSWIRE
Ligand Announces Record Date and Details for Distribution for OmniAb Spin-Off
03 Oct 2022 //
BUSINESSWIRE
Ligand Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
03 Oct 2022 //
BUSINESSWIRE
Ligand Reports Second Quarter 2022 Financial Results
08 Aug 2022 //
BUSINESS WIRE
Ligand Pharma Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
01 Aug 2022 //
BUSINESSWIRE
Ligand to Report Second Quarter Financial Results on August 8
22 Jul 2022 //
BUSINESSWIRE
Ligand Pharmaceuticals Appoints Jason Haas to its Board of Directors
29 Jun 2022 //
BUSINESSWIRE
Ligand Reports First Quarter 2022 Financial Results
04 May 2022 //
BUSINESSWIRE
Ligand to Report First Quarter Financial Results on May 4
19 Apr 2022 //
BUSINESSWIRE
